Pomalidomide-PEG1-C2-NH2

Background Introduction

Pomalidomide-PEG1-C2-NH2 is a versatile E3 ligase ligand-linker conjugate commonly used in the development of targeted protein degradation therapies, particularly PROTACs (Proteolysis Targeting Chimeras). By combining pomalidomide—an immunomodulatory drug that recruits the E3 ligase cereblon (CRBN)—with a polyethylene glycol (PEG1) spacer and a C2-amino linker, this molecule provides a reliable and modular platform for attaching protein-targeting ligands, which enables the creation of custom PROTAC molecules.

Mechanism

Pomalidomide-PEG1-C2-NH2 functions as a bifunctional tool in PROTAC design. The pomalidomide moiety binds selectively to the CRBN E3 ubiquitin ligase, recruiting this complex to the target protein. The PEG1-C2 linker offers rigidity and optimal spacing for effective ubiquitination. When the C2-amino linker is conjugated to a ligand specific for a target protein, the resulting PROTAC molecule brings the target protein into proximity with the CRBN E3 ligase, promoting polyubiquitination and subsequent proteasomal degradation of the target protein. This provides a catalytic, event-driven mode of action, in contrast to traditional inhibition.

Applications

Pomalidomide-PEG1-C2-NH2 is widely used in the synthesis of PROTACs designed to selectively degrade disease-causing proteins involved in cancer, neurodegeneration, and immunological disorders. It serves as a key building block for researchers developing next-generation targeted therapies, enabling rapid construction and evaluation of various PROTAC candidates. Additionally, its modular design is suitable for in vitro and in vivo studies, structure-activity relationship (SAR) exploration, and high-throughput screening campaigns in drug discovery.

Pomalidomide-PEG1-C2-NH2 serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation through its optimized structural components. This molecule provides a detailed description of the linker, ligand, and selection of target protein ligands.

Linker: The linker in Pomalidomide-PEG1-C2-NH2 is a polyethylene glycol (PEG) unit with one ethylene glycol repeat, offering moderate flexibility and a short length. Its non-cleavable nature ensures stability, maintaining the integrity of the conjugate during cellular processes.

Ligand: The ligand component, pomalidomide, is a thalidomide derivative known for its high-affinity binding to the cereblon E3 ubiquitin ligase. Its structural characteristics provide a robust platform for recruiting the ligase complex, enhancing the efficiency of protein ubiquitination.

Reactive Site: The reactive site features an amine group (NH2) at the terminal end of the linker, which is well-suited for coupling with carboxyl-functionalized target protein ligands. Recommended reaction types include amide bond formation, facilitating stable conjugate assembly.

Recommended Target Protein Ligand: The ideal warhead for this conjugate is a small molecule with a carboxyl group, allowing for efficient amide linkage to the NH2 reactive site. This configuration enhances the specificity and efficacy of protein degradation by ensuring precise targeting. Such warheads are particularly advantageous in experimental studies focused on elucidating protein function and validating therapeutic targets.